Abpro

What Abpro does

Abpro is a clinical-stage biopharmaceutical company developing next-generation bispecific and multi-specific antibody therapeutics for cancer and ophthalmologic diseases. Founded in 2007 and headquartered in Burlington, Massachusetts, the company operates two proprietary technology platforms: DiversImmune® for antibody discovery and MultiMab™ for engineering, both centered on the TetraBi tetravalent bispecific T-cell engager format. The format is designed to provide bivalent binding to tumor-associated antigens, Fc modification for reduced toxicity and extended half-life, and a symmetrical structure enabling manufacturing efficiency.

Abpro's clinical pipeline comprises four core candidates: ABP-102 (HER2 x CD3 for HER2-positive solid tumors, partnered worldwide with Celltrion, FDA IND cleared January 2026 with Phase 1 planned for H1 2026), ABP-201 (VEGF/ANG-2 for wet age-related macular degeneration and diabetic macular edema, held through majority-owned subsidiary AbMed Corporation with AstraZeneca/MedImmune licensing and Abpro Bio for Asian markets), ABP-150 (Claudin 18.2 x CD3 for gastric cancer, partnered with NJCTTQ in China and Thailand), and ABP-110 (GPC3 x CD3 for hepatocellular carcinoma, licensed from the National Cancer Institute). The company previously developed COVID-19 neutralizing antibodies ABP-300 and ABP-310.

The business model is partnership-driven rather than commercialized direct sales. Abpro is pre-revenue and generates cash primarily through upfront payments, equity investments, and development and net sales milestones from pharmaceutical partners under licensing and co-development agreements. Celltrion is the anchor partner for the lead asset with up to $1.75 billion in potential net sales milestones, and AbMed received a $30 million equity investment from Abpro Bio in 2020. Abpro became publicly traded in December 2024 via a SPAC merger with Atlantic Coastal Acquisition Corp. II but is facing Nasdaq delisting as of February 2026 due to minimum equity noncompliance, alongside governance disruptions including the March 2025 CEO departure and January 2026 board resignations.

Name

Abpro

Legal name

Abpro Holdings, Inc.

Website

https://abpro.co

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Abpro is a clinical-stage biopharmaceutical company developing next-generation bispecific antibody therapeutics using its proprietary DiversImmune® and MultiMab™ platforms, partnered with global pharma firms to treat cancer and ophthalmologic diseases.

Ownership category

akta.pro rank

Product category

Bispecific Antibody Therapeutics (Oncology and Ophthalmology Biopharmaceuticals)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Bispecific antibody therapeutics
• Immuno-oncology drug development
• Antibody discovery platforms
• T-cell engager therapies
• Biopharmaceutical pipeline development

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Partnership and Milestone Payments: Abpro receives upfront payments, equity investments, and is eligible for development and net sales milestone payments under collaboration agreements with pharmaceutical partners. Under the Celltrion collaboration, the company received single digit million dollars upfront and is eligible for up to $1.75 billion in net sales milestones and up to $4.0 million in development milestones.
2. Future Product Revenue: Pre-revenue clinical stage biotech company expecting to generate revenue through product sales upon regulatory approval and commercialization of pipeline candidates including ABP-102, ABP-201, ABP-150, and ABP-110

Go-to-market motion2 records

Distribution channels4 records

Marketing channels3 records

Core offering

Abpro is a clinical-stage biopharmaceutical company that discovers and develops next-generation bispecific and multi-specific antibody therapeutics for cancer and ophthalmologic diseases. Its pipeline candidates (ABP-102, ABP-201, ABP-150, ABP-110) are built on the proprietary DiversImmune® antibody discovery platform, MultiMab™ antibody engineering platform, and the TetraBi tetravalent bispecific T-cell engager format, and are advanced through strategic co-development and licensing partnerships with global pharmaceutical companies.

Product overview

Abpro is a biopharmaceutical company developing next-generation antibody therapies using two proprietary technology platforms: DiversImmune® for antibody discovery and MultiMab™ for antibody engineering. The company leverages its TetraBi tetravalent bispecific antibody format for T-cell engagement. Abpro's pipeline includes four clinical-stage bispecific antibody candidates: ABP-102 (HER2/CD3 for HER2+ solid tumors, partnered with Celltrion), ABP-201 (VEGF/ANG-2 for wet AMD and diabetic macular edema, via AbMed subsidiary with AstraZeneca licensing), ABP-150 (Claudin 18.2/CD3 for gastric cancer, partnered with NJCTTQ), and ABP-110 (GPC3/CD3 for hepatocellular carcinoma, licensed from NCI). The company also developed COVID-19 antibodies (ABP-300, ABP-310) and has additional pipeline candidates including ABP 310 for COVID and ABP-201 for wet AMD.

Differentiator

Problem solved

Functional benefit

Brands

• DiversImmune®: Antibody discovery platform used to generate therapeutic building blocks - high affinity and high specificity antibodies with functional activity against therapeutic targets.
• MultiMab™
• TetraBi™

Products and services

• ABP-102 (ABP-102/CT-P72) A next-generation TetraBi bispecific antibody targeting HER2 and CD3 for the treatment of HER2-positive solid tumors, including breast and gastric cancers. Features bivalent HER2 binding sites with affinity tuning to selectively target tumor cells expressing high and intermediate levels of HER2 while reducing activity on healthy tissues. Co-developed worldwide with Celltrion Inc.
• ABP-201 A bispecific antibody designed to simultaneously inhibit VEGF and ANG-2 for the potential treatment of vascular diseases of the eye, including diabetic macular edema (DME) and wet age-related macular degeneration (Wet AMD). Held through majority-owned subsidiary AbMed Corporation, with worldwide rights licensed from AstraZeneca/MedImmune and regional rights licensed to Abpro Bio in Asia/Middle East/CIS countries.
• ABP-150 A TetraBi antibody targeting Claudin 18.2 and CD3 for the potential treatment of gastric cancers. Designed to bind bivalently to Claudin 18.2 on gastric cancer cells and to CD3 on cytotoxic T cells, leading to T-cell-mediated killing of gastric tumor cells. Abpro retains worldwide commercialization rights; NJCTTQ holds exclusive rights in China and Thailand.
• ABP-110 A TetraBi antibody targeting GPC3 and CD3 for the potential treatment of hepatocellular carcinoma (HCC), the major form of liver cancer. Designed to bind bivalently to GPC3 on HCC cells and CD3 on cytotoxic T cells, triggering sustained T-cell activation and tumor cell killing. Licensed worldwide from the National Cancer Institute (NCI/NIH) effective August 1, 2017.
• DiversImmune® Antibody Discovery Platform Proprietary antibody discovery platform used to generate therapeutic antibody building blocks—high affinity and high specificity antibodies with functional activity against therapeutic targets. Available as a technology platform underlying Abpro's pipeline and available for partnership.
• MultiMab™ Antibody Engineering Platform Proprietary antibody engineering platform used to construct therapeutic product candidates by assembling antibody building blocks into different combinations of bi- and multi-specific antibodies. Underpins Abpro's TetraBi format and pipeline.
• TetraBi Antibody Format A tetravalent bispecific T-cell engager antibody format offering bivalent binding to tumor-associated antigens for potentially increased efficacy, Fc modification for reducing toxicity and increasing antibody half-life, and flexible configuration for increased safety and/or maximized efficacy. Foundational technology underlying Abpro's pipeline candidates.

Quantifiable outcome

• ABP-102/CT-P72 received FDA IND clearance enabling Phase 1 trial initiation in H1 2026 for HER2+ solid tumors
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Celltrion Inc.flagshipStrategic or Co-development Partner · 1 September 2022Worldwide strategic partnership for development and commercialization of ABP-102/CT-P72, a bispecific HER2 x CD3 T-cell engager. Abpro received single digit million dollars upfront and equity investment, eligible for up to $1.75 billion in net sales milestones and up to $4.0 million in development milestones. Celltrion responsible for CMC, in vivo preclinical work, clinical development, and worldwide commercialization. Abpro responsible for in vitro pre-clinical work.
• Abpro Bio International (Abpro Bio Co. Ltd)coreStrategic or Co-development Partner · 1 January 2020Collaboration and License Agreement for ABP-201 in Asia and Middle East. Abpro Bio granted exclusive rights in China, Japan, South Korea, Southeast Asia, Middle East, and CIS countries. AbMed received $30 million equity investment from Abpro Bio in connection with this agreement.
• Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd (NJCTTQ)coreStrategic or Co-development Partner · 1 February 2019Partnership for development of multiple novel bispecific antibodies including ABP-150 (Claudin 18.2 x CD3). NJCTTQ holds exclusive commercialization rights in China and Thailand; Abpro retains worldwide commercialization rights for ABP-150.
• National Cancer Institute (NCI/NIH)coreStrategic or Co-development Partner · 1 August 2017Patent license granted by NCI for worldwide exclusive rights to ABP-110 (GPC3/CD3 bispecific antibody) for treatment of GPC-3 expressing liver cancer using particular moiety for targeting GPC3.
• AstraZeneca (formerly MedImmune)coreStrategic or Co-development Partner · 1 August 2016Collaboration and license agreement through majority-owned subsidiary AbMed Corporation. MedImmune/AstraZeneca granted exclusive worldwide license for ANG-2/VEGF-H1RK bispecific antibodies. Abpro holds 82% of AbMed, AstraZeneca holds remainder. Lead candidate ABP-201 targeting VEGF/ANG2 anticipated to enter Phase 1 in H2 2025.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Adagene: Clinical-stage biotech with POWERbody and SAFEbody antibody platforms for bispecific and conditionally active antibodies. Comparable platform-licensing business model and early clinical stage to Abpro.
• Zymeworks: Clinical-stage biotech developing bispecific and multispecific antibody therapeutics using proprietary platforms (Azymetric, EFECT). Most directly comparable to Abpro in platform-based bispecific antibody discovery with multiple clinical-stage oncology candidates.
• Genmab: Established antibody therapeutics company with the DuoBody bispecific platform and a portfolio of clinical and commercial-stage bispecific antibodies (including approved Epkinly). Comparable technology foundation to Abpro's MultiMab and broader pipeline ambition.
• Harpoon Therapeutics: Developed T-cell engager bispecific antibodies (TriTAC platform) before acquisition by Merck. Closely analogous to Abpro's TetraBi T-cell engager focus and partnered-program structure prior to acquisition.
• MacroGenics: Clinical-stage biotech with DART and TRIDENT platforms for bispecific and multi-specific antibodies, including T-cell engagers. Direct competitor to Abpro's TetraBi format in HER2 and other oncology targets.
• Compass Therapeutics: Clinical-stage biotech developing bispecific antibodies for oncology, including T-cell engagers. Comparable size and pipeline stage to Abpro with similarly platform-driven approach to multi-specific antibody development.
• Xencor: Clinical-stage biotech with the XmAb antibody engineering platform used to develop bispecific antibodies and T-cell engagers. Directly comparable to Abpro as a platform-based bispecific developer with multiple partnered programs.

Broad incumbents

• AstraZeneca: Global biopharma and existing Abpro partner through AbMed Corporation for ANG-2/VEGF bispecifics. A relevant incumbent both as a comparison point for bispecific R&D capacity and as the partner validating Abpro's AbMed platform economics.
• Regeneron Pharmaceuticals: Major biopharma with approved bispecific antibodies (e.g., Linvoseltamab-class programs, Veopoz) and the VelociBi antibody platform. Represents the scaled end-state Abpro could aspire to as a platform-driven bispecific developer.

Regional players

• Zai Lab: China-headquartered clinical-stage biopharma licensing and developing bispecific antibodies and oncology therapeutics in Asia. Comparable role to NJCTTQ/Abpro Bio as a regional commercialization partner for next-generation antibody programs in China and broader Asia.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/abprolabs
• LinkedInlinkedin.com/company/abpro

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds8 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abpro